Business Context and Reporting Period
Company: Palisade Bio, Inc. (PALI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. Its lead product candidate, PALI-2108, is a prodrug inhibitor targeting phosphodiesterase-4 (PDE4) for the treatment of Inflammatory Bowel Disease (IBD), specifically Ulcerative Colitis (UC) and Fibrostenotic Crohn's Disease (FSCD). The company has no approved products and has never generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $250 |
| Net Loss | $(14,438) | $(12,300) |
| Operating Expenses | $14,859 | $13,320 |
| Research & Development | $9,063 | $6,893 |
| General & Administrative | $5,796 | $6,202 |
| Cash and Cash Equivalents (Year End) | $9,821 | $12,432 |
| Net Cash Used in Operating Activities | $(12,193) | $(11,133) |
| Net Cash Provided by Financing Activities | $9,582 | $11,186 |
Liquidity: As of December 31, 2024, the company held approximately $9.8 million in cash and cash equivalents. Management estimates this is sufficient to fund operations through the fourth quarter of 2025.
Material Changes vs. Prior Period
- Revenue: Revenue decreased to $0 in 2024 from $250,000 in 2023. The 2023 revenue was a one-time license milestone payment from a co-development agreement with Newsoara regarding a legacy asset (LB1148), which was terminated in 2023.
- Net Loss: Net loss increased by approximately 17% to $14.4 million in 2024 from $12.3 million in 2023.
- R&D Expenses: Increased by 31% ($2.2 million) primarily due to higher joint development costs for PALI-2108 ($4.3 million in 2024 vs. $0.7 million in 2023) and increased drug manufacturing costs. This was partially offset by a decrease in clinical trial expenses related to the terminated legacy asset.
- Financing Activity: The company raised approximately $9.6 million in net cash through financing activities in 2024, including a December 2024 underwritten public offering ($4.1 million net), a May 2024 private placement ($3.5 million net), and a February 2024 warrant inducement transaction ($2.2 million net).
Guidance, Outlook, and Risks
Outlook and Milestones
- Phase 1 Trial: The Phase 1 clinical trial of PALI-2108 in Canada commenced in November 2024. Topline data is anticipated in the second quarter of 2025.
- Future Trials: If Phase 1 objectives are met, the company plans to initiate Phase 1b/2a studies in Q1 2026. An Investigational New Drug (IND) application for U.S. trials is expected to be submitted in 2025.
- Capital Needs: The company expects to require additional financing by the end of 2025 to continue operations at the expected level.
Material Risks and Contingencies
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year following the issuance of the financial statements due to recurring losses and the need for additional capital.
- Internal Controls: A material weakness in internal control over financial reporting was identified and remains unremediated as of December 31, 2024, related to a lack of segregation of duties and formalized processes for journal entries and reconciliations.
- Regulatory Uncertainty: There is no guarantee that the FDA will accept data from the Canadian Phase 1 trial, which could delay or prevent U.S. clinical development.
- Stock Listing: The company's stock price has traded below the $1.00 minimum bid price requirement for Nasdaq listing in early 2025, creating a risk of delisting if compliance is not maintained.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $9.8 million cash balance to fund the Phase 1 trial and operations through late 2025, given the "substantial doubt" going concern warning.
- Financing Terms: Review the terms of the December 2024 and May 2024 equity offerings, specifically the dilution impact of the prefunded warrants and the repricing of existing warrants.
- Internal Control Remediation: Monitor progress on remediation of the material weakness in internal controls to ensure future financial reporting reliability.
- Clinical Data: Await the Q2 2025 topline data from the Canadian Phase 1 trial to assess the safety and tolerability of PALI-2108.
- Nasdaq Compliance: Track the stock price to ensure it remains above the $1.00 threshold to avoid delisting proceedings.